Search Results

You are looking at 101 - 110 of 295 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Lessons From Adaptive Randomization: Spying the I-SPY2 Trial in Breast Cancer

Bishal Gyawali and Saroj Niraula

.gov identifier: NCT01042379 ). The arms consist of one common control arm of standard neoadjuvant chemotherapy with paclitaxel (with an alternate control arm of paclitaxel + trastuzumab or pertuzumab + trastuzumab if HER2-positive) against which other

Full access

NCCN Guidelines® Updates

... or in a delayed procedure in patients with extranodal extension .” Removed bullet: “Neoadjuvant chemotherapy should be considered the standard (prior to ILND) in patients with ≥4 cm inguinal lymph nodes, if FNA is positive for metastatic penile

Full access

Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer

Ronald C. Chen, William U. Shipley, Jason A. Efstathiou, and Anthony L. Zietman

than among those in bladder preservation studies. For example, the median age of patients in the US Intergroup trial comparing cystectomy with or without neoadjuvant chemotherapy was 63 years, 21 whereas that for BC2001 (radiation with

Full access

Predictors of Outcome in Bladder Cancer

John B. Eifler, Daniel A. Barocas, and Matthew J. Resnick

schedules may be individualized based on the EORTC or CUETO risk score. Muscle-Invasive Bladder Cancer Patient Selection for Neoadjuvant Chemotherapy A landmark randomized controlled trial published in 2003 (SWOG-8710) demonstrated that patients

Full access

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Margaret von Mehren, John M. Kane, Mark Agulnik, Marilyn M. Bui, Janai Carr-Ascher, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Ricardo J. Gonzalez, Ashley Holder, Jade Homsi, Vicki Keedy, Ciara M. Kelly, Edward Kim, David Liebner, Martin McCarter, Sean V. McGarry, Nathan W. Mesko, Christian Meyer, Alberto S. Pappo, Amanda M. Parkes, Ivy A. Petersen, Seth M. Pollack, Matthew Poppe, Richard F. Riedel, Scott Schuetze, Jacob Shabason, Jason K. Sicklick, Matthew B. Spraker, Melissa Zimel, Lisa E. Hang, Hema Sundar, and Mary Anne Bergman

sarcoma. Preliminary results suggest promising local control and OS rates. 32 Chemotherapy/Chemoradiation Resectable Disease Neoadjuvant Therapy Neoadjuvant chemotherapy 33 – 37 or chemoradiation 38 – 47 has been evaluated in single and

Full access

FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma

Amro M. Abdelrahman, Ajit H. Goenka, Roberto Alva-Ruiz, Jennifer A. Yonkus, Jennifer L. Leiting, Rondell P. Graham, Kenneth W. Merrell, Cornelius A. Thiels, Christopher L. Hallemeier, Susanne G. Warner, Michael G. Haddock, Travis E. Grotz, Nguyen H. Tran, Rory L. Smoot, Wen Wee Ma, Sean P. Cleary, Robert R. McWilliams, David M. Nagorney, Thorvardur R. Halfdanarson, Michael L. Kendrick, and Mark J. Truty

/leucovorin/irinotecan/fluorouracil) or gemcitabine/nab-paclitaxel as first-line neoadjuvant chemotherapy, with 94 (46.5%) undergoing chemotherapy switch and the majority (91%) undergoing preoperative chemoradiation post-NAT. There were 135 (67%) patients with an elevated CA 19-9 level

Full access

Rectal Cancer

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

Sebag-Montefiore D . Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study . J Clin Oncol 2006 ; 24 : 4664 – 4665 ; author reply 4665–4666 . 88 Bosset JF Calais G Mineur L . Enhanced tumorocidal effect of

Full access

Diagnostic and Treatment Considerations When Newly Diagnosed Breast Cancer Coincides With Pregnancy: A Case Report and Review of Literature

Lauren Nye, Timothy K. Huyck, and William J. Gradishar

obtained, which did not suggest distant metastases. Treatment options, including mastectomy, breast-conserving therapy with axillary staging, and neoadjuvant chemotherapy, were discussed extensively with the patient. Throughout the discussion, the patient

Full access

Neoadjuvant Treatment Approaches for Stage II–III Rectal Cancer

Presented by: Steven Nurkin

experimental arm received neoadjuvant chemotherapy with FOLFIRINOX (fluorouracil/leucovorin/irinotecan/oxaliplatin) for 6 cycles, CRT, TME, and 3 months of adjuvant chemotherapy with modified FOLFOX6 or capecitabine. The standard-of-care group received CRT, TME

Full access

Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer

Bin-Yi Xiao, Xuan Zhang, Tai-Yuan Cao, Dan-Dan Li, Wu Jiang, Ling-Heng Kong, Jing-Hua Tang, Kai Han, Chen-Zhi Zhang, Wei-Jian Mei, Jian Xiao, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, and Pei-Rong Ding

Even worse, in a study evaluating MMR status and chemosensitivity, more than one-fourth of dMMR rectal cancers were found to progress after neoadjuvant chemotherapy. 11 The success of PD-1 blockade for dMMR mCRC has prompted attempts to validate its